Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells
出版年份 2016 全文链接
标题
Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells
作者
关键词
-
出版物
CANCER SCIENCE
Volume 107, Issue 12, Pages 1877-1887
出版商
Wiley
发表日期
2016-10-11
DOI
10.1111/cas.13093
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study
- (2016) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer
- (2015) Peter M. Ellis et al. Clinical Lung Cancer
- Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
- (2015) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
- (2015) Eleonore Beurel et al. PHARMACOLOGY & THERAPEUTICS
- Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment
- (2015) Xiaoqi Liu Translational Oncology
- BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
- (2015) Lijia Chen et al. ACS Medicinal Chemistry Letters
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- Overexpression of Human ABCB1 in Cancer Cells Leads to Reduced Activity of GSK461364, a Specific Inhibitor of Polo-like Kinase 1
- (2014) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1
- (2013) Chung-Pu Wu et al. BIOCHEMICAL PHARMACOLOGY
- An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
- (2013) Walter M. Stadler et al. CANCER
- Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical Genetics
- (2012) Mark E. Burkard et al. ACS Chemical Biology
- Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance
- (2012) Alexander Levitzki Annual Review of Pharmacology and Toxicology
- From Plk1 to Plk5
- (2011) Guillermo de Cárcer et al. CELL CYCLE
- Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
- (2011) D. Olmos et al. CLINICAL CANCER RESEARCH
- A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
- (2011) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Functional availability of γ-herpesvirus K-cyclin is regulated by cellular CDK6 and p16INK4a
- (2010) Hidenori Yoshioka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis
- (2009) A. G. Gilmartin et al. CANCER RESEARCH
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- Apoptotic signaling by c-MYC
- (2008) B Hoffman et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now